Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 8Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Carcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thoracic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Nonhematologic Malignancies 1Non-Squamous Non-Small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1NSCLC 1Metatropic dwarfism 1Metastatic HER2-positive Breast Cancer 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1Desmoplastic Small Round Cell Tumor 1

Interventions

Capecitabine 2Vinorelbine 1Trastuzumab 1Lapatinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2-positive Advanced Breast Cancer × Vinorelbine × Clear all
NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
420 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡